Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Aura Biosciences Inc (AURA)
:AURA
AURA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$6.63 - $12.38
Previous CloseN/A
Volume82.15K
Average Volume (3M)143.04K
Market Cap
$381.13M
Enterprise Value$287.21M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta2.31
Next Earnings
Mar 12, 2025EPS Estimate
-0.44Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.73
Shares Outstanding49,951,466
10 Day Avg. Volume162,143
30 Day Avg. Volume143,037
Standard Deviation0.16
R-Squared0.00802
Alpha-0.00640
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-6.20
P/FCF Ratio0.00
Enterprise Value/Market Cap0.75
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-221.78
Enterprise Value/Ebitda-3.13
Forecast
1Y Price Target
$22.00Price Target Upside192.94% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
---
Aura Biosciences Inc News
PremiumCompany Announcements
Aura Biosciences Reports Q3 Financial Results
PremiumCompany Announcements
Aura Biosciences Reports Positive Phase 1 Trial Results---
Bulls Say, Bears Say
Bulls Say
Pipeline DevelopmentAURA reported preliminary Phase 1 bladder cancer data showing bel-sar’s direct cytotoxic effect and immune activation.
Safety ProfileBel-sar displayed a highly favorable safety profile with no posterior inflammation, no treatment-related serious adverse events, and no Grade 3-5 treatment-related adverse events.
Bears Say
Regulatory DelaysThe approval for the Phase 3 CoMpass trial in the EU was granted later than anticipated, though timelines for data readout remain unchanged.
---
Ownership Overview
3.96% Insiders
20.13% Mutual Funds
52.17% Other Institutional Investors
14.95% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
AURA FAQ
What was Aura Biosciences Inc’s price range in the past 12 months?
Aura Biosciences Inc lowest stock price was $6.63 and its highest was $12.38 in the past 12 months.
What is Aura Biosciences Inc’s market cap?
Aura Biosciences Inc’s market cap is $381.13M.
When is Aura Biosciences Inc’s upcoming earnings report date?
Aura Biosciences Inc’s upcoming earnings report date is Mar 12, 2025 which is in 18 days.
How were Aura Biosciences Inc’s earnings last quarter?
Aura Biosciences Inc released its earnings results on Nov 12, 2024. The company reported -$0.42 earnings per share for the quarter, beating the consensus estimate of -$0.441 by $0.021.
Is Aura Biosciences Inc overvalued?
According to Wall Street analysts Aura Biosciences Inc’s price is currently Undervalued.
Does Aura Biosciences Inc pay dividends?
Aura Biosciences Inc does not currently pay dividends.
What is Aura Biosciences Inc’s EPS estimate?
Aura Biosciences Inc’s EPS estimate is -0.44.
How many shares outstanding does Aura Biosciences Inc have?
Aura Biosciences Inc has 49,951,466 shares outstanding.
What happened to Aura Biosciences Inc’s price movement after its last earnings report?
Aura Biosciences Inc reported an EPS of -$0.42 in its last earnings report, beating expectations of -$0.441. Following the earnings report the stock price went down -3.005%.
Which hedge fund is a major shareholder of Aura Biosciences Inc?
Currently, no hedge funds are holding shares in AURA
---
Aura Biosciences Inc Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$22.00 (192.94% Upside)
$22.00 (192.94% Upside)
Blogger Sentiment
Bullish
AURA Sentiment 70%
Sector Average 70%
Sector Average 70%
Insider Transactions
Sold Shares
Worth $334.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 3.3%
Last 30 Days ▼ 8.0%
Last 30 Days ▼ 8.0%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-14.65%
12-Months-Change
Fundamentals
Return on Equity
-50.99%
Trailing 12-Months
Asset Growth
14.23%
Trailing 12-Months
Company Description
Aura Biosciences Inc
Aura Biosciences Inc is a clinical-stage oncology company developing a novel technology platform based on virus-like drug conjugates to target and destroy cancer cells selectively while activating the immune system to create long lasting anti-tumor immunity.
---
AURA Stock 12 Month Forecast
Average Price Target
$22.00
▲(192.94% Upside)
Technical Analysis
Sarepta Therapeutics
―
Editas Medicine
―
Intellia Therapeutics
―
Crispr Therapeutics AG
―
Beam Therapeutics
―
Best Analysts Covering AURA
1 Year
1 Year Success Rate
2/12 ratings generated profit
1 Year Average Return
-13.99%
reiterated a buy rating 3 months ago
Copying Julian Harrison's trades and holding each position for 1 Year would result in 16.67% of your transactions generating a profit, with an average return of -13.99% per trade.
---